Skip to main content

 4G16 | pdb_00004g16

Crystal structure of ck1g3 with 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2-YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 
    0.250 (Depositor), 0.244 (DCC) 
  • R-Value Work: 
    0.237 (Depositor), 0.230 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 4G16

Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history. 

Literature

2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1g)inhibitors

Hua, Z., Huang, X., Bregman, H., Chakka, N., DiMauro, E.F., Doherty, E.M., Goldstein, J., Gunaydin, H., Huang, H., Mercede, S., Newcomb, J., Patel, V.F., Turci, S.M., Yan, J., Wilson, C., Martin, M.W.

(2012) Bioorg Med Chem Lett 22: 5392-5395

  • DOI: https://doi.org/10.1016/j.bmcl.2012.07.046
  • Primary Citation Related Structures: 
    4G16, 4G17

  • PubMed Abstract: 

    Screening of the Amgen compound library led to the identification of 2-phenylamino-6-cyano-1H-benzimidazole 1a as a potent CK1 gamma inhibitor with excellent kinase selectivity and unprecedented CK1 isoform selectivity. Further structure-based optimization of this series resulted in the discovery of 1h which possessed good enzymatic and cellular potency, excellent CK1 isoform and kinase selectivity, and acceptable pharmacokinetic properties.


  • Organizational Affiliation: 
    • Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA. zihao.hua@amgen.com

Macromolecule Content 

  • Total Structure Weight: 38.86 kDa 
  • Atom Count: 2,734 
  • Modeled Residue Count: 302 
  • Deposited Residue Count: 330 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Casein kinase I isoform gamma-3330Homo sapiensMutation(s): 0 
Gene Names: CSNK1G3
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9Y6M4 (Homo sapiens)
Explore Q9Y6M4 
Go to UniProtKB:  Q9Y6M4
PHAROS:  Q9Y6M4
GTEx:  ENSG00000151292 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9Y6M4
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
0VM

Query on 0VM



Download:Ideal Coordinates CCD File
B [auth A]2-[(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)amino]-1H-benzimidazole-6-carbonitrile
C20 H12 F3 N5 O
GAHCTGQCJXQYNK-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
0VM BindingDB:  4G16 IC50: 6560 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free:  0.250 (Depositor), 0.244 (DCC) 
  • R-Value Work:  0.237 (Depositor), 0.230 (DCC) 
Space Group: P 31 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 57.153α = 90
b = 57.153β = 90
c = 223.431γ = 120
Software Package:
Software NamePurpose
HKL-2000data collection
AMoREphasing
CNSrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

  • Released Date: 2013-05-22 
  • Deposition Author(s): Huang, X.

Revision History  (Full details and data files)

  • Version 1.0: 2013-05-22
    Type: Initial release
  • Version 1.1: 2018-01-24
    Changes: Structure summary
  • Version 1.2: 2023-09-13
    Changes: Data collection, Database references, Derived calculations, Refinement description